3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
5
Neoplasms
4
Prostatic Neoplasms
3
Oligodendroglioma
2
Neoplasm Metastasis
2
Nasopharyngeal Carcinoma
2
Multiple Myeloma
2
Melanoma
2
Glioma
2
Glioblastoma
2
Esophageal Neoplasms
2
Brain Neoplasms
2
Astrocytoma
2
Anus Neoplasms
2
Weight Loss
1
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Thrombocytopenia
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Splenomegaly
1
Skin Neoplasms
1
Interventions
Gemcitabine
23
Capecitabine
17
Cisplatin
11
Oxaliplatin
10
Fluorouracil
9
Leucovorin
8
Irinotecan
7
Erlotinib Hydrochloride
6
pembrolizumab
5
Radiotherapy
5
Sorafenib
4
Interleukin-12 Subunit p35
3
Cholangiopancreatography, Endoscopic Retrograde
3
Carboplatin
3
regorafenib
2
dehydroftorafur
2
Watchful Waiting
2
Trastuzumab
2
Pancreaticoduodenectomy
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Long-Term Synaptic Depression
2
Lapatinib
2
Filgrastim
2
Epirubicin
2
Drug Therapy
2
Dihematoporphyrin Ether
2
Chemotherapy, Adjuvant
2
Bevacizumab
2
trifluridine tipiracil drug combination
1
tremelimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Bile Duct Neoplasms
×
Quality of Life
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled